-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
Vice Governor Hu Qisheng visited Shijiazhuang No.4 Pharmaceutical Group for a research visit.
Category:
Time：2021-09-30
On September 28, Hu Qisheng, Vice Governor of Hebei Province, visited pharmaceutical companies including Shijiazhuang Fourth Pharmaceutical Group to conduct a research tour on the innovative development of the pharmaceutical industry and to assess the implementation of solutions to issues raised by enterprises.
On September 28, Hu Qisheng, Vice Governor of Hebei Province, visited pharmaceutical companies including Shijiazhuang Fourth Pharmaceutical Group to conduct a research tour on the innovative development of the pharmaceutical industry and the implementation of solutions to issues raised by enterprises. He urged that the deployment of the provincial Party committee and provincial government be earnestly carried out, the construction of a new, modernized pharmaceutical industry system be accelerated, new competitive advantages be forged, industrial transformation and upgrading be promoted, and high-quality development of the province’s pharmaceutical industry be fostered.
Hu Qisheng and his delegation visited the Pharmaceutical Research Institute of Shijiazhuang No. 4 Pharmaceutical Group, where they gained a detailed understanding of the company’s innovative R&D efforts, industrial planning, production and operations, and talent development. They also had an in-depth exchange with enterprise leaders, including Qu Jiguang, Chairman of the Board of Directors of Shijiazhuang No. 4 Pharmaceutical Group. They highly praised the company’s sense of responsibility and effective practices in driving growth through innovation, taking proactive measures, and continuously striving to become stronger, bigger, and better. He enthusiastically encouraged the company to seize opportunities, keep up the good work, highlight its unique strengths and advantages, and make greater contributions and assume greater responsibilities in promoting the innovative, green, and high-quality development of Hebei’s pharmaceutical industry.
Hu Qisheng pointed out that the pharmaceutical industry is closely linked to people’s health and well-being as well as the cultivation of new growth drivers, and it boasts vast market potential. Enterprises must remain committed to regarding innovation as the primary driving force behind high-quality development, strive for scientific and technological self-reliance and strength, increase R&D investment, boost the enthusiasm of scientific and technological personnel, and accelerate the industrialization of research findings—using innovation to secure a bright future.
Hu Qisheng called for all relevant departments at various levels to earnestly implement the “Several Measures for Supporting the Development of the Pharmaceutical Industry.” They should focus on the cutting edge of the industry and emerging trends, adopting a comprehensive approach that encompasses innovation, talent development, environmental protection, and going public. This will help guide enterprises to raise product standards, build high-end brands, and actively attract upstream and downstream enterprises—such as those specializing in pharmaceutical packaging materials—to accelerate the overall enhancement of the pharmaceutical industry’s competitiveness. It is essential to carry out the “Triple Focus, Four Innovations, Five Optimization” campaign in depth, fulfill responsibility-sharing arrangements, optimize the business environment, gain a deeper understanding of enterprises’ concerns, aspirations, and expectations, and enhance the precision, effectiveness, and value of industrial policies. We must spare no effort to assist enterprises in overcoming their challenges and accelerate the high-quality development of the pharmaceutical industry.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license